Q2 2021

Source filing unavailable

Q2 2021 · —

Revenue

$268.00K

no prior Q2 2020 on file

Net Income

-$1.09M

no prior Q2 2020 on file

EPS Diluted

-$0.46

no prior Q2 2020 on file

Gross Profit-$33,000—

Operating Income-$1,055,000—

Operating Cash Flowderived

Same quarter

no prior Q2 2020 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR

VBIOValion Bio, Inc.